CD163 and acute myeloid leukemia: The correlation study between CD163 expression and AML clinical status revealed that age, cytogenetic risk, molecular risk, and FAB subtype were closely related to CD163 expression (Figure 10E–H), suggesting an inverse correlation between CD163 expression and the clinical status and prognosis of AML.